Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics Inc (NQ: DRMA )

1.750 -0.500 (-22.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 488,661
Open 2.280
Bid (Size) 1.790 (1)
Ask (Size) 1.850 (3)
Prev. Close 2.250
Today's Range 1.750 - 2.300
52wk Range 1.290 - 17.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-80.23%
-80.23%
1 Month
-18.60%
-18.60%
3 Month
-26.78%
-26.78%
6 Month
-70.83%
-70.83%
1 Year
-89.58%
-89.58%

More News

Read More
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into Dermata Therapeutics's Recent Short Interest
Via Benzinga
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?
Via InvestorPlace
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Via ACCESSWIRE
Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024
Via InvestorPlace
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Dermata Therapeutics Shares Are Trading Over 100%: What You Need To Know
Via Benzinga
Nasdaq Down 2%; Alphabet Posts Upbeat Earnings
Via Benzinga
Why Is Azitra (AZTR) Stock Down 75% Today?
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Is Nuzee (NUZE) Stock Up 133% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.